Trials / Recruiting
RecruitingNCT06497361
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
Safety and Efficacy of PRG-2311 (CD19/BCMA-targeting CAR-T Cells) for Refractory Lupus Nephritis and IgG4-Related Disease
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Tongji Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PRG-2311 | PRG-2311 (CD19/BCMA-targeting CAR-T Cells) |
Timeline
- Start date
- 2024-07-01
- Primary completion
- 2027-07-01
- Completion
- 2028-07-01
- First posted
- 2024-07-11
- Last updated
- 2024-07-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06497361. Inclusion in this directory is not an endorsement.